NUCHAL TRANSLUCENCY CANNOT BE USED AS A SCREENING TEST FOR CHROMOSOMAL ABNORMALITIES IN THE FIRST TRIMESTER OF PREGNANCY IN A ROUTINE ULTRASOUND PRACTICE

1996 ◽  
Vol 16 (9) ◽  
pp. 797-805 ◽  
Author(s):  
L. H. KORNMAN ◽  
L. P. MORSSINK ◽  
J. R. BEEKHUIS ◽  
B. T. H. M. DE WOLF ◽  
M. P. HERINGA ◽  
...  
Keyword(s):  
Screening Test ◽  
Chromosomal Abnormalities ◽  
First Trimester ◽  
Nuchal Translucency ◽  
First Trimester Of Pregnancy

scholarly journals Ultrasound Markers of Aneuploidy in the First Trimester

2017 ◽  
Vol 11 (1) ◽  
pp. 20-28
Author(s):  
Zoran Belics ◽  
Zoltán Papp
Keyword(s):  
Chromosomal Aberrations ◽  
Prenatal Screening ◽  
Chromosomal Abnormalities ◽  
Early Recognition ◽  
False Positive Rate ◽  
First Trimester ◽  
Nuchal Translucency ◽  
First Trimester Of Pregnancy ◽  
High Standards ◽  
Screening Sensitivity

ABSTRACT Prenatal screening of fetal aneuploidy is a continuously and rapidly evolving area of research; there have been tremendous advancements over the past decades in prenatal screening for aneuploidy, especially during the first trimester. As there is extensive evidence that effective screening for major chromosomal abnormalities can be provided in the first trimester of pregnancy, recently we have changed our practice; the prenatal screening of fetal chromosomal aberrations has been moved and pointed to the first trimester. Besides the nuchal translucency, which is one of the most known ultrasonographic markers, there are other markers, which can be examined during the first trimester of pregnancy. To maximize the quality of sonography, increase the screening sensitivity, and decrease the range of false-positive rate, all of the first-trimester ultrasound markers have well-established criteria for the measurement. With the use of high standards of scanning, the early recognition of sonographic markers of chromosomal aberrations can be helpful in forward prenatal diagnosis. On the contrary, the early diagnosis makes the termination of the pregnancy possible with fewer complications, and there is time for planning of further follow-up and interventions. How to cite this article Belics Z, Papp Z. Ultrasound Markers of Aneuploidy in the First Trimester. Donald School J Ultrasound Obstet Gynecol 2017;11(1):20-28.

scholarly journals Prenatal Detection of Fetal Anomalies at the 11- to 13-Week Scan—Part I: Brain, Face and Neck

2013 ◽  
Vol 7 (4) ◽  
pp. 359-368 ◽  
Author(s):  
Tamara Illescas ◽  
Waldo Sepulveda ◽  
Begona Adiego ◽  
Pilar Martinez-Ten
Keyword(s):  
Fetal Brain ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Ultrasound Screening ◽  
Second Trimester ◽  
Fetal Anomalies ◽  
Prenatal Detection ◽  
Ultrasound Findings ◽  
First Trimester Of Pregnancy ◽  
Structural Anomalies

ABSTRACT In the last 20 years, the role of first-trimester ultrasound screening has expanded from individual calculation of the risk of aneuploidy through measurement of the nuchal translucency to a powerful technique to evaluate important aspects of the fetal anatomy. Traditionally, the full anatomy scan for detection of structural anomalies has been performed in the second trimester of pregnancy. However, with the implementation of the first-trimester scan at 11 to 13 weeks of gestation many of the structural anomalies traditionally detected in the second trimester can now be identified earlier in pregnancy. In the first part of this review we discuss the main ultrasound findings that may facilitate the prenatal detection of fetal brain, face and neck abnormalities in the first trimester of pregnancy. How to cite this article Sepulveda W, Illescas T, Adiego B, Martinez-Ten P. Prenatal Detection of Fetal Anomalies at the 11- to 13-Week Scan—Part I: Brain, Face and Neck. Donald School J Ultrasound Obstet Gynecol 2013;7(4):359-368.

scholarly journals Hydroxychloroquine and the Prevention of Pregnancy Losses

2019 ◽  
pp. 359-366
Author(s):  
Frishman M ◽  
Radin M ◽  
Cecchi I ◽  
Sciascia S ◽  
Schreiber K
Keyword(s):  
Connective Tissue ◽  
Antiphospholipid Antibodies ◽  
Pregnancy Loss ◽  
Chromosomal Abnormalities ◽  
Connective Tissue Diseases ◽  
First Trimester ◽  
Pregnancy Complication ◽  
Distinct Entity ◽  
Consecutive Pregnancy ◽  
First Trimester Of Pregnancy

Pregnancy loss is a common and devastating pregnancy complication. Recurrent early miscarriage (REM) isdefined as two or more consecutive pregnancy losses during the first trimester of pregnancy. It is a distinct entity and in approximately 50% of these patients, the underlying cause is never established. REM can be idiopathic, i.e. of unknown cause, be related to infections, anatomical or chromosomal abnormalities and can also be related to the presence of autoimmune connective tissue diseases or antiphospholipid antibodies (aPL). Hydroxychloroquine (HCQ) is an antimalarial immunomodulator and is currently being investigated for its role in the prevention of idiopathic REM and REM related to antiphospholipid antibodies (aPL). In this article we review the evidence that exists to date regarding the use of HCQ in the setting of unexplained REM and REM in relation to connective tissue diseases and aPL and antiphospholipid syndrome (APS).

Sign in / Sign up

Export Citation Format

Share Document